Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02651727
Title Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advanced Cancer Subjects
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Verastem, Inc.

pancreatic adenocarcinoma

Advanced Solid Tumor


Gemcitabine + Nab-paclitaxel + VS-4718

Age Groups: adult
Covered Countries USA

No variant requirements are available.